Annexin A3 as a Prognostic Biomarker for Breast Cancer: A Retrospective Study

Table 1

Relationship between ANXA3 expression and clinical characteristics in breast cancer tissue.

	Number of cases ()	ANXA3-negative ()	ANXA3-positive ()	ANXA3 positive rate (%)	χ^2	value
Age (years)					0.365	0.546
<50	145	57	88	60.69
≥50	164	59	105	64.02
Menopausal status					1.560	0.240
Premenopausal	158	54	104	65.82
Postmenopausal	151	62	89	58.94
Tumor size (cm)					1.532	0.465
≤2	117	39	78	66.67
>2, ≤5	160	65	95	59.37
>5	32	12	20	62.50
Clinical stage					0.607	0.738
I	54	20	34	62.96
II	221	79	142	64.25
III	34	10	24	70.59
Molecular subtyping					9.226	0.026
Lu A	65	27	38	58.46
Lu B	148	62	86	58.11
HER-2 type	37	15	22	59.46
Triple-negative	59	12	47	79.66
Lymphatic metastasis					11.123	0.004
0	129	62	67	51.94
1–3	108	35	73	67.59
>3	72	19	53	73.61
Histological grade					16.686	<0.001
I	35	24	11	31.42
II	192	67	125	65.10
III	82	25	57	69.51